The company said it saw the biggest revenue growth in its instruments business, which gained 32 percent year over year.
Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.
The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
Fueled by an NIH SBIR grant, analytics firm Cytobank is building out its machine-learning algorithms and adding pipelines to support big-picture research.
Fluidigm reported that its mass cytometry revenues jumped 32 percent while genomics revenues fell 5 percent year over year.
A 30 percent decrease in instrument revenue was tempered by a 23 percent uptick in consumables revenue.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.
The company gains global distribution rights for the Zurich team's histoCAT cytometry imaging software, which it will sell alongside its newly-launched Hyperion Imaging System.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.